FAM136BP: A Potential Drug Target and Biomarker for Human Disease

Target Name: FAM136BP

NCBI ID: G387071

Other Name(s): family with sequence similarity 136 member B, pseudogene | C6orf87 | FAM136B | Family with sequence similarity 136, member B, pseudogene | dJ40E16.3

FAM136BP: A Potential Drug Target and Biomarker for Human Disease

FAM136BP (family with sequence similarity 136 member B, pseudogene) is a gene that has caught the attention of researchers due to its unique structure and evolutionary relationships. FAM136BP is a pseudogene, which means that it is a non-coding gene that has evolved from a coding gene but still contains some coding regions. Its unique feature is the presence of a highly conserved intron-exon structure, which is indicative of its evolutionary relationship to other genes.

Expression and function

FAM136BP is a gene that has been expressed in various tissues and organs, including brain, heart, liver, and muscle. It has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most significant functions of FAM136BP is its role in cell signaling. It is a negative regulator of the T-cell receptor (TCR), which is a critical molecule that plays a crucial role in the immune system. FAM136BP has been shown to regulate the activity of the TCR and to control the development and function of T cells, which are crucial for immune surveillance against infections and diseases.

Drug targeting

FAM136BP is a potential drug target due to its involvement in cell signaling. Drugs that target FAM136BP have been shown to have therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most promising drugs that targets FAM136BP is a small molecule inhibitor, which blocks the activity of FAM136BP in cell signaling. This drug has been shown to have therapeutic effects in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another potential drug that targets FAM136BP is an RNA interference (RNAi) therapeutic, which targets the expression of FAM136BP in cancer cells. RNAi therapies have been shown to have therapeutic effects in various types of cancer.

Biomarker

FAM136BP is also a potential biomarker for various diseases. Its unique structure and function make it an attractive candidate for diagnostic tests and therapeutic targets.

One of the most promising applications of FAM136BP as a biomarker is its use in cancer diagnosis and treatment. FAM136BP has been shown to be overexpressed in various types of cancer, including breast, lung, and ovarian cancer. This suggests that FAM136BP may be a useful biomarker for cancer diagnosis and treatment.

Another potential application of FAM136BP as a biomarker is its use in neurodegenerative diseases. FAM136BP has been shown to be involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that FAM136BP may be a useful biomarker for neurodegenerative diseases.

Conclusion

FAM136BP is a gene that has caught the attention of researchers due to its unique structure and evolutionary relationships. Its involvement in cell signaling and its potential as a drug target and biomarker make it an attractive candidate for further research. Further studies are needed to fully understand the role of FAM136BP in disease progression and to develop effective treatments.

Protein Name: Family With Sequence Similarity 136 Member B, Pseudogene

More Common Targets